AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Association of Plastic Surgeons 2013 Annual Meeting
Data from on-going Ranger® Registry to be Poster Presentations at Major Plastic Surgery Conference
Alachua, FL (PRWEB) April 19, 2013
AxoGen, Inc. (OTCBB: AXGN) a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today the presentation of two posters submitted by study investigators based on clinical use of Avance® Nerve Graft at the American Association of Plastic Surgeons (AAPS) Annual Meeting, being held April 20-23, 2013 in New Orleans, LA. The two studies being presented will report on findings from the RANGER® Registry, an on-going multi-center utilization and outcomes study for Avance® Nerve Graft, a processed nerve allograft for the repair and reconstruction of peripheral nerve segmental defects. AxoGen will also host a booth to exhibit its products at the AAPS conference.
Study investigators Bauback Safa, MD, and Gregory Buncke, MD of The Buncke Clinic in San Francisco, CA, submitted “Multicenter Observational Study of 215 Nerve Repairs with Processed Nerve Allograft,” based on data from the second data milestone in the Ranger® Registry, which increased the dataset to include 157 subjects with 215 nerve repairs from 18 centers and 36 surgeons.
The second poster, “Evaluating Nerve Repair Outcomes after 105 Nerve Reconstructions in the Upper Extremity Utilizing Processed Nerve Allografts,” was authored by 11 investigators from the Ranger® Registry and reports on results from a subset of patients who required complex nerve reconstructions (traumatic nerve injuries requiring extensive resection of damaged nerve tissue and/or debridement and repair of the surrounding wound bed). This subset included 81 subjects with 105 nerve repairs, including 55 repairs that were classified as complex nerve reconstructions. 18 centers and 32 surgeons contributed to this dataset.
Karen Zaderej, CEO of AxoGen , said, “The Ranger® Registry is the largest, published, multi-center, peripheral nerve study to date and continues to enroll new patients and we are pleased to share the data at AAPS.” Ms. Zaderej continued, “The data included in these posters help advance our understanding of the new treatment algorithm being established as a result of the availability of Avance® Processed donated human nerve tissue. ”
Avance® Nerve Graft is processed nerve allograft (human) intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. The product provides surgeons a readily-available nerve graft to repair peripheral nerves damaged by trauma or resected during a surgical procedure.
For more information on AxoGen and its technology, please visit http://www.axogeninc.com.
About AxoGen, Inc.
AxoGen (AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company´s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen´s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at http://www.axogeninc.com.
AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen´s principal executive office and operations are located in Alachua, FL. To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/4/prweb10647828.htm